This database contains 105 studies, archived under the term: "metabolism"
Click here to filter this large number of results.
Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects
Willenborg, B.,
Schmoller, A.,
Caspary, J.,
Melchert, U. H.,
Scholand-Engler, H. G.,
Jauch-Chara, K.,
Hohagen, F.,
Schweiger, U.,
Oltmanns, K. M.
Context: The risk to develop dementia is significantly increased in diabetes mellitus. Memantine, an N-methyl-D-aspartate receptor antagonist, which is clinically applied in dementia, has been shown to exert neuroprotective effects under hypoglycemic conditions in rats.; Objective: We hypothesized that memantine may prevent hypoglycemia-induced decrements in the cerebral high-energy phosphate, i.e. ATP, metabolism to exert its […]
Cognitive Improvement during Treatment for Mild Alzheimer’s Disease with a Chinese Herbal Formula: A Randomized Controlled Trial
Zhang, Y.,
Lin, C.,
Zhang, L.,
Cui, Y.,
Gu, Y.,
Guo, J.,
Wu, D.,
Li, Q.,
Song, W.
OBJECTIVES: To explore the efficacy of Chinese herbal formula compared with donepezil 5 mg/day in patients with mild Alzheimer’s disease (AD). METHODS: Patients with mild AD meeting the criteria were randomized into Chinese herbal formula Yishen Huazhuo decoction (YHD) group and donepezil hydrochloride (DH) group during the 24-week trial. The outcomes were measured by ADAS-cog, […]
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease
Gillette-Guyonnet, Sophie,
Andrieu, Sandrine,
Dantoine, Thierry,
Dartigues, Jean-François,
Touchon, Jacques,
Vellas, B.
Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer’s disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial […]
Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD
Silverman, Daniel H. S.,
Geist, Cheri L.,
Kenna, Heather A.,
Williams, Katherine,
Wroolie, Tonita,
Powers, Bevin,
Brooks, John,
Rasgon, Natalie L.
Differential cerebral metabolic effects of various hormone therapy formulations, and their associations with cognitive status, remain to be established. The principal aim of the current study was to assess relationships between regional cerebral metabolism and estrogen-based hormone therapies. Postmenopausal women (n=53) at elevated risk for Alzheimer’s disease (AD) were on estrogen-containing hormone therapy for at […]
Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes
Nakagawa, Kiyotaka,
Kiko, Takehiro,
Miyazawa, Taiki,
Carpentero Burdeos, Gregor,
Kimura, Fumiko,
Satoh, Akira,
Miyazawa, Teruo
Phospholipid hydroperoxides (PLOOH) accumulate abnormally in the erythrocytes of dementia patients, and dietary xanthophylls (polar carotenoids such as astaxanthin) are hypothesised to prevent the accumulation. In the present study, we conducted a randomised, double-blind, placebo-controlled human trial to assess the efficacy of 12-week astaxanthin supplementation (6 or 12 mg/d) on both astaxanthin and PLOOH levels in […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]
Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease
Chen, Y.,
Wolk, D. A.,
Reddin, J. S.,
Korczykowski, M.,
Martinez, P. M.,
Musiek, E. S.,
Newberg, A. B.,
Julin, P.,
Arnold, S. E.,
Greenberg, J. H.,
Detre, J. A.
Objective: We compared the ability of arterial spin labeling (ASL), an MRI method that measures cerebral blood flow (CBF), to that of FDG-PET in distinguishing patients with Alzheimer disease (AD) from healthy, age-matched controls.; Methods: Fifteen patients with AD (mean age 72 ± 6 years, Mini-Mental State Examination score [MMSE] 20 ± 6) and 19 […]
Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment
Bayer-Carter, Jennifer L.,
Green, Pattie S.,
Montine, Thomas J.,
VanFossen, Brian,
Baker, Laura D.,
Watson, G. Stennis,
Bonner, Laura M.,
Callaghan, Maureen,
Leverenz, James B.,
Walter, Brooke K.,
Tsai, Elaine,
Plymate, Stephen R.,
Postupna, Nadia,
Wilkinson, Charles W.,
Zhang, Jing,
Lampe, Johanna,
Kahn, Steven E.,
Craft, Suzanne
Objective: To compare the effects of a 4-week high-saturated fat/high-glycemic index (HIGH) diet with a low-saturated fat/low-glycemic index (LOW) diet on insulin and lipid metabolism, cerebrospinal fluid (CSF) markers of Alzheimer disease, and cognition for healthy adults and adults with amnestic mild cognitive impairment (aMCI).; Design: Randomized controlled trial.; Setting: Veterans Affairs Medical Center clinical […]